Trial Profile

Phase 2 Study of Sonelokimab for palmo-plantar pustulosis (PPP)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonelokimab (Primary)
Indications Palmoplantar pustulosis
Focus Therapeutic Use
Acronyms LEDA

Most Recent Events

12 May 2025 According to a MoonLake Immunotherapeutics media release, primary end point readout from the trial expected in 2H 2025.
12 May 2025 According to a MoonLake Immunotherapeutics media release, the Company held an in-person and virtual Capital Markets Update in New York on Tuesday, April 29, 2025 and presented an interim readout.
25 Apr 2025 According to a MoonLake Immunotherapeutics media release, the trial design of LEDA trial has been informed by previous successful studies of sonelokimab, including the landmark Phase 2 MIRA trial in hidradenitis suppurativa which identified the optimal dosing.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com